article thumbnail

CancerVar: A New Bioinformatics Tool Developed for Clinical Interpretation of Cancer Mutations

XTalks

CancerVar will help researchers standardize and automate clinical interpretations for 13 million somatic mutations from 1,911 cancer census genes. The gene mutations that cause sporadic cancer occur only in the tumor cells and are acquired during an individual’s life, not inherited.

article thumbnail

UK research partners team up to accelerate MND drug discovery

Drug Discovery World

Identifying genes linked with MND A key part of the MND Translational Challenge therapeutic strategy is to validate and de-risk MND targets using human genetic evidence. The proposed programme uses bioinformatics approaches and experimental models to validate and de-risk a portfolio of potential MND therapeutic targets.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

Such information can reveal details about tumor staging, tumor progression, heterogeneity, gene mutations and clonal evolution. Liquid Biopsy Use in Oncology Clinical Trials. Optimal methods for bioinformatic analysis are still needed. These tumor-derived entities are used to derive genomic and proteomic data.

article thumbnail

Drug discovery deals highlight key growth areas

Drug Discovery World

GenomeFrontier will use their virus-free cell and gene engineering platforms and Quantum Engine cell-engineering system to manufacture the CAR-T therapy for use in a Phase I clinical trial. Anders Grøn, CEO at Clinical Microbiomics, said: “We are a company made up of scientists – Innovation is at the heart of our DNA.

Drugs 52
article thumbnail

LabCorp Backs Resolution Bioscience’s Liquid Biopsy Test for NSCLC

XTalks

Related: Liquid Biopsies Help Match Cancer Patients to Phase I Trials. The test is based on the detection of actionable genesgenes with known driver mutations that can be targeted by an approved therapy (or investigational therapies in clinical trials). Personalized Approach.

Gene 105
article thumbnail

Tuesday 18 April at AACR Annual Meeting 2023

Drug Discovery World

Among individuals who consented to whole-exome sequencing and were identified as carriers of predisposition genes for hereditary breast and ovarian cancer (HBOC) or Lynch syndrome, 39.2% would not have qualified for genetic screening under current guidelines, according to results from the Tapestry clinical trial presented at AACR 2023 today.

article thumbnail

Researchers identify immune targets for chemotherapy-resistant breast cancers

Drug Discovery World

To investigate the immune environment that surrounds these chemotherapy-resistant tumours, the researchers employed multiple and novel complementary technologies looking at proteins and genes on both pre-treatment and post-treatment breast cancer tissue. This would need to be investigated in future clinical trials.